Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study.
Nikesh DattaniJoseph ShalhoubSandip NandhraTristan LaneAbdulsalam Abu-OwnAhmed ElbastyAled JonesAndrew DuncanAndrew GarnhamAnkur ThaparAnna MurrayAnzar BaigAthanasios SaratzisAtif SharifBella HuasenClaire DawkinsCraig NesbittDaniel CarradiceDarren MorrowDavid BosanquetEamon KavanaghFaisal ShaikhGergely GosiGraeme AmblerGregory FultonGurdas SinghHannah TraversHayley MooreJames OlivierLouise HitchmanMartin O'DonohoeMatthew PopplewellMekki MedaniMichael JenkinsMingzheng A GohOliver LyonsOlivia McBridePaul MoxeyPhilip StatherPhillipa BurnsRachel ForsytheRachel SamRanjeet BrarRobert BrightwellRuth BensonSarah OnidaSharath ParavastuSimon LambracosSrinivasa R VallabhaneniStewart WalshTasleem AktarTony MoloneyZola MzimbaIsaac K NyamekyePublished in: Phlebology (2020)
The main findings from this study were that there was 'good' or 'very good' consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.